{ "schemaVersion": 1, "organisationId": "O-2686c53790c44e9c967b0e148da71e6c", "slug": "fresenius-medical-care", "name": "FRESENIUS MEDICAL CARE", "updatedAt": "2026-03-20T05:46:05.849954Z", "sections": [ { "type": "OVERVIEW", "text": "Fresenius Medical Care is a healthcare company focused on kidney care, with dialysis and related products and services as its core business. The company describes itself as a leading provider for people with kidney disease and is vertically integrated across two main operating segments: Care Delivery, which provides dialysis and related health care services, and Care Enablement, which manufactures and distributes kidney-care medical devices, systems, pharmaceuticals and other products. Its core offerings include hemodialysis, peritoneal dialysis and acute dialysis therapies, as well as associated machines, dialyzers, bloodline systems, concentrates, water treatment systems and digital support tools. [P-66da8ceb7d174ca0b755a1eb2c3368db][P-cdde888b368c44ee9498f42ac5552baf][P-10243a243bc8449999da8922f18b7143][P-9278f43ca1684630ac62650923f53bb0][P-0ac8208a937b4a2ca23cd96aab8159b6][P-96acd32038b94429b7decd602de9dac5]\n\nThe company has a broad international footprint, operating 3,675 dialysis centers in around 40 countries and serving 299,352 dialysis patients at year-end 2024, while also selling products to customers in around 150 countries and running 39 production sites in 19 countries. Fresenius Medical Care states that its mission is to provide the best possible care in diverse health care systems for a growing number of patients around the world, sustainably. As general indicators of scale, the company generated €19.336 billion of revenue in 2024 and employed 111,513 people worldwide at year-end 2024. [P-2ed1a34ef4ba43eeb7bc0be18b305407][P-d5237be42a5c4e8abe5416d4e5f1dbe0][P-563b058320f14075b7c01eaa9f30ca1f][P-eaeb619f7b2c4cfaaa986b84e8075e33][P-bea819012cb841c5a9d19b3667aadec6]\n[P-66da8ceb7d174ca0b755a1eb2c3368db][P-cdde888b368c44ee9498f42ac5552baf][P-10243a243bc8449999da8922f18b7143][P-9278f43ca1684630ac62650923f53bb0][P-0ac8208a937b4a2ca23cd96aab8159b6][P-96acd32038b94429b7decd602de9dac5][P-2ed1a34ef4ba43eeb7bc0be18b305407][P-d5237be42a5c4e8abe5416d4e5f1dbe0][P-563b058320f14075b7c01eaa9f30ca1f][P-eaeb619f7b2c4cfaaa986b84e8075e33][P-bea819012cb841c5a9d19b3667aadec6]", "updatedAt": "2026-03-20T05:46:05.849954Z" }, { "type": "PRODUCTS", "text": "Fresenius Medical Care’s product portfolio centers on renal therapies and related devices. Its Care Enablement products include dialyzers, in-center hemodialysis machines, home dialysis and peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, water treatment systems, acute cardiopulmonary products, apheresis products, and other medical devices. In hemodialysis, the company says it offers machines, dialyzers, bloodline systems, HD solutions and concentrates, water treatment systems, and data processing and analysis systems for both clinics and home use. In peritoneal dialysis, it offers systems and solutions for continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD), again for both center-based and home treatment. It also describes acute cardiopulmonary products and apheresis therapy products, including devices used to remove excess blood fats or pathogenic antibodies.[P-96acd32038b94429b7decd602de9dac5][P-9278f43ca1684630ac62650923f53bb0][P-4ad495b7432642adaa3a6072df558d94][P-b4bc76841178404b960a82a567f57f94]\n\nNamed products discussed by the company include the 5008X hemodialysis system, which it says became the first FDA-approved machine capable of delivering high-volume hemodiafiltration (HVHDF) in the U.S.; FMC states that, when paired with the FX CorAL dialyzer, the system combines advanced engineering and membrane technologies to enable HVHDF. The FX CorAL dialyzer uses the company’s Helixone hydro membrane, which forms a gel-like water layer on the membrane surface to reduce protein adsorption and lower immune-response induction while maintaining selective permeability for toxin and excess-water removal. In acute dialysis, the multiFiltratePRO platform is positioned for ICU use in continuous renal replacement therapy; FMC says it added a hemoperfusion mode in 2024, is developing a new monitor and secure connectivity board, and introduced multiHL7 to integrate machine data with patient monitoring systems, patient data management systems, and electronic medical records. It also launched the Ready4 multiFiltratePRO augmented-reality training application to help ICU users build proficiency with the device. In apheresis, the company identifies APRED, its Apheresis Pathogen Reduction Device, as a therapeutic apheresis platform.[P-0a2a14945bd5470db3967f4a5996d7af][P-9d7a4a81bf0d4d24a35fcd35fa5325ce][P-493b54dd197e456bb561da71e893419e][P-44af83d3808c4fe9bbdac30a8fd200b7][P-ae44902d8a294042802c06554d6b72d1][P-1c63f33a09ca4e87ac2a66f73d6ecb7e]\n\nService and support offerings tied to the product business include maintenance agreements for health care products, and the broader service portfolio includes ESRD-related treatments, ESRD laboratory testing services, acute dialysis services, value- and risk-based care programs, pharmacy services, vascular specialty and ambulatory surgery center services, physician nephrology practice management, and ambulant treatment services. The company also states that it provides care and care-coordination services for certain ESRD and chronic kidney disease patients under shared-savings arrangements. In 2024, dialyzers remained its largest product group, with about 174 million units produced, or around 40% of the global HD dialyzer market; FMC also said about 51,000 of an estimated 100,000 HD machines installed globally in 2024 were produced by the company, and that more than 75% of home hemodialysis patients used one of its machines. On reported segment data, health care products revenue was €4.19 billion in 2024, versus total external revenue of €19.34 billion, implying that products represented about 22% of total revenue.[P-95bea03894e4451180554cd49907d9aa][P-811aac18fb0f44058116be85f2d967a2][P-925f1c8626eb487999326f479491533b][P-eb8c1c8b4d5348d88be6c730cb3cd683][P-2e173e8ab8f940e3a66be5484f5b30d0][T-7b39a412d8b5439fac390900621caddd]\n[P-96acd32038b94429b7decd602de9dac5][P-9278f43ca1684630ac62650923f53bb0][P-4ad495b7432642adaa3a6072df558d94][P-b4bc76841178404b960a82a567f57f94][P-0a2a14945bd5470db3967f4a5996d7af][P-9d7a4a81bf0d4d24a35fcd35fa5325ce][P-493b54dd197e456bb561da71e893419e][P-44af83d3808c4fe9bbdac30a8fd200b7][P-ae44902d8a294042802c06554d6b72d1][P-1c63f33a09ca4e87ac2a66f73d6ecb7e][P-95bea03894e4451180554cd49907d9aa][P-811aac18fb0f44058116be85f2d967a2][P-925f1c8626eb487999326f479491533b][P-eb8c1c8b4d5348d88be6c730cb3cd683][P-2e173e8ab8f940e3a66be5484f5b30d0][T-7b39a412d8b5439fac390900621caddd]", "updatedAt": "2026-03-20T05:46:05.849954Z" }, { "type": "GEOGRAPHY", "text": "Fresenius Medical Care is headquartered in Bad Homburg v. d. Höhe, Germany, and operates a global dialysis-clinic network spanning around 40 countries; it also sells products and services to customers in around 150 countries worldwide.[P-514ec2e5112e4f0499e0ad653820bf97][P-02da7354e2374483b6ddd79c8d3a6c6c][P-d5237be42a5c4e8abe5416d4e5f1dbe0] Its disclosed geographic revenue presentation is concentrated in the U.S.: in 2024, external customer revenue was €13.67 billion from the U.S. (about 70.7% of total), €479.0 million from Germany (about 2.5%), and €5.19 billion from the rest of the world (about 26.8%), with revenue attributed based on end-user location for products and service location for services.[P-a784ab5350a14515a6fd7c015f87f5de][T-c0163f88a0da47c2a84277c536463375]\n\nThe company’s workforce is also weighted toward North America: 72,430 employees, or 62% of total headcount, were in North America at year-end 2024, versus 27,525 in Europe, the Middle East and Africa (23%), 14,179 in Asia-Pacific (12%), and 3,598 in Latin America (3%).[T-dd6ce8e784754f8ea0231b427e37f7da] Its regional organization includes entities and offices in locations such as Bad Homburg and Vienna in EMEA, New York in North America, Jaguariúna in Brazil, and Sydney, Tokyo, and Singapore in Asia-Pacific.[T-7e4039cdf5294d0299af040d96522106][T-67d458ef27494ee8bbafb3edf4af9209]\n\nManufacturing and supply are similarly international. Fresenius Medical Care operates 39 production sites in 19 countries, supported by 23 distribution centers, with major plants in St. Wendel and Schweinfurt in Germany, Ogden, Utah in the U.S., Changshu in China, L'Arbresle in France, Buzen in Japan, and Reynosa in Mexico.[P-d5237be42a5c4e8abe5416d4e5f1dbe0][P-3f5db0a05b684e99acc8743c0ee2752e][P-c4d567f19b88421a8b9149afce4140d4]\n[P-514ec2e5112e4f0499e0ad653820bf97][P-02da7354e2374483b6ddd79c8d3a6c6c][P-d5237be42a5c4e8abe5416d4e5f1dbe0][P-a784ab5350a14515a6fd7c015f87f5de][T-c0163f88a0da47c2a84277c536463375][T-dd6ce8e784754f8ea0231b427e37f7da][T-7e4039cdf5294d0299af040d96522106][T-67d458ef27494ee8bbafb3edf4af9209][P-3f5db0a05b684e99acc8743c0ee2752e][P-c4d567f19b88421a8b9149afce4140d4]", "updatedAt": "2026-03-20T05:46:05.849954Z" }, { "type": "SEGMENTS", "text": "Fresenius Medical Care reports two official operating and reportable segments: Care Delivery and Care Enablement [P-b66d69f0452f4585904084ad50668cd4]. Care Delivery is the clinical-services segment, centered on the company’s global dialysis clinic networks and related kidney-care services; the Fresenius Kidney Care and NephroCare networks comprised 3,675 dialysis clinics worldwide in 2024 [P-677e2c9fe6b94bd58a1952c747743402][P-1163a4eaa462403e9c7bad061244d9ec]. Care Enablement is the products and solutions segment, covering in-center dialysis, home dialysis, and critical care product verticals, along with manufacturing, supply chain, commercial operations, and research and development [P-8d78232027664986b1821a5b7619af2d][P-7854d7d6997a4fa8ab48c2b9546d43a3].\n\nBased on 2024 revenue from external customers, Care Delivery contributed about 79.0% of group revenue (€15.28 billion of €19.34 billion), while Care Enablement contributed about 21.0% (€4.06 billion) [T-7b39a412d8b5439fac390900621caddd]. Within Care Delivery, external revenue was primarily health care services (€13.47 billion), with smaller contributions from insurance contracts (€1.61 billion) and health care products (€0.19 billion) [T-7b39a412d8b5439fac390900621caddd]. Within Care Enablement, external revenue was almost entirely health care products (€4.00 billion), plus a small lease-contract component (€0.06 billion) [T-7b39a412d8b5439fac390900621caddd]. If measured before inter-segment eliminations, the 2024 mix was approximately 73.3% Care Delivery and 26.7% Care Enablement, reflecting substantial internal sales from Care Enablement into Care Delivery [T-7b39a412d8b5439fac390900621caddd].\n[P-b66d69f0452f4585904084ad50668cd4][P-677e2c9fe6b94bd58a1952c747743402][P-1163a4eaa462403e9c7bad061244d9ec][P-8d78232027664986b1821a5b7619af2d][P-7854d7d6997a4fa8ab48c2b9546d43a3][T-7b39a412d8b5439fac390900621caddd]", "updatedAt": "2026-03-20T05:46:05.849954Z" }, { "type": "HISTORY", "text": "Fresenius Medical Care was created in 1996, when Fresenius merged its dialysis business with U.S.-based National Medical Care, and the company was listed on the Frankfurt and New York exchanges that same year.[https://freseniusmedicalcare.com/en/about-us/history/25-years/][https://freseniusmedicalcare.com/en-us/company/our-company/news-releases/fmcna-25-anniversary-celebration/] \n\nIts subsequent history was shaped largely by expansion in dialysis services and products through acquisitions. Fresenius Medical Care completed the acquisition of Renal Care Group in 2006, acquired Gambro’s worldwide peritoneal dialysis business in 2010, and closed its acquisition of Liberty Dialysis Holdings in 2012.[https://www.fresenius.com/node/4724][https://www.fresenius.com/node/4837][https://www.fresenius.com/node/4555] In 2019, it completed the acquisition of NxStage Medical, which the company described as a milestone in its home dialysis strategy.[https://www.freseniusmedicalcare.com/en-us/company/our-company/news-releases/fresenius-medical-care-completes-acquisition-of-nxstage-medical/][P-132714c30ae64acbba414ffedcefbb06] A later structural milestone came in 2023, when shareholders approved changing the company’s legal form from a KGaA to an AG, with the conversion becoming effective on November 30, 2023.[P-637047581a39412fa712a921bed2954b][P-0462157b5fa24161848308acfee8d87b]\n[P-132714c30ae64acbba414ffedcefbb06][P-637047581a39412fa712a921bed2954b][P-0462157b5fa24161848308acfee8d87b][https://freseniusmedicalcare.com/en/about-us/history/25-years/][https://freseniusmedicalcare.com/en-us/company/our-company/news-releases/fmcna-25-anniversary-celebration/][https://www.fresenius.com/node/4724][https://www.fresenius.com/node/4837][https://www.fresenius.com/node/4555][https://www.freseniusmedicalcare.com/en-us/company/our-company/news-releases/fresenius-medical-care-completes-acquisition-of-nxstage-medical/]", "updatedAt": "2026-03-20T05:46:05.849954Z" } ], "sources": [ { "id": "P-66da8ceb7d174ca0b755a1eb2c3368db", "href": "https://app.finbar.com/go?id=P-66da8ceb7d174ca0b755a1eb2c3368db", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p3", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 3 }, { "id": "P-cdde888b368c44ee9498f42ac5552baf", "href": "https://app.finbar.com/go?id=P-cdde888b368c44ee9498f42ac5552baf", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p52", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 52 }, { "id": "P-10243a243bc8449999da8922f18b7143", "href": "https://app.finbar.com/go?id=P-10243a243bc8449999da8922f18b7143", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p170", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 170 }, { "id": "P-9278f43ca1684630ac62650923f53bb0", "href": "https://app.finbar.com/go?id=P-9278f43ca1684630ac62650923f53bb0", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p30", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 30 }, { "id": "P-0ac8208a937b4a2ca23cd96aab8159b6", "href": "https://app.finbar.com/go?id=P-0ac8208a937b4a2ca23cd96aab8159b6", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p30", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 30 }, { "id": "P-96acd32038b94429b7decd602de9dac5", "href": "https://app.finbar.com/go?id=P-96acd32038b94429b7decd602de9dac5", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p30", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 30 }, { "id": "P-2ed1a34ef4ba43eeb7bc0be18b305407", "href": "https://app.finbar.com/go?id=P-2ed1a34ef4ba43eeb7bc0be18b305407", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p28", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 28 }, { "id": "P-d5237be42a5c4e8abe5416d4e5f1dbe0", "href": "https://app.finbar.com/go?id=P-d5237be42a5c4e8abe5416d4e5f1dbe0", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p52", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 52 }, { "id": "P-563b058320f14075b7c01eaa9f30ca1f", "href": "https://app.finbar.com/go?id=P-563b058320f14075b7c01eaa9f30ca1f", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p4", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 4 }, { "id": "P-eaeb619f7b2c4cfaaa986b84e8075e33", "href": "https://app.finbar.com/go?id=P-eaeb619f7b2c4cfaaa986b84e8075e33", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p76", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 76 }, { "id": "P-bea819012cb841c5a9d19b3667aadec6", "href": "https://app.finbar.com/go?id=P-bea819012cb841c5a9d19b3667aadec6", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p113", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 113 }, { "id": "P-4ad495b7432642adaa3a6072df558d94", "href": "https://app.finbar.com/go?id=P-4ad495b7432642adaa3a6072df558d94", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p30", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 30 }, { "id": "P-b4bc76841178404b960a82a567f57f94", "href": "https://app.finbar.com/go?id=P-b4bc76841178404b960a82a567f57f94", "label": "FRESENIUS MEDICAL CARE — Full financial report (2023 Y), p33", "documentId": "D-2ee6c4ff21644c7392a5420f46e71ce7", "page": 33 }, { "id": "P-0a2a14945bd5470db3967f4a5996d7af", "href": "https://app.finbar.com/go?id=P-0a2a14945bd5470db3967f4a5996d7af", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p190", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 190 }, { "id": "P-9d7a4a81bf0d4d24a35fcd35fa5325ce", "href": "https://app.finbar.com/go?id=P-9d7a4a81bf0d4d24a35fcd35fa5325ce", "label": "FRESENIUS MEDICAL CARE — Full financial report (2023 Y), p45", "documentId": "D-2ee6c4ff21644c7392a5420f46e71ce7", "page": 45 }, { "id": "P-493b54dd197e456bb561da71e893419e", "href": "https://app.finbar.com/go?id=P-493b54dd197e456bb561da71e893419e", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p38", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 38 }, { "id": "P-44af83d3808c4fe9bbdac30a8fd200b7", "href": "https://app.finbar.com/go?id=P-44af83d3808c4fe9bbdac30a8fd200b7", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p38", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 38 }, { "id": "P-ae44902d8a294042802c06554d6b72d1", "href": "https://app.finbar.com/go?id=P-ae44902d8a294042802c06554d6b72d1", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p38", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 38 }, { "id": "P-1c63f33a09ca4e87ac2a66f73d6ecb7e", "href": "https://app.finbar.com/go?id=P-1c63f33a09ca4e87ac2a66f73d6ecb7e", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p38", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 38 }, { "id": "P-95bea03894e4451180554cd49907d9aa", "href": "https://app.finbar.com/go?id=P-95bea03894e4451180554cd49907d9aa", "label": "FRESENIUS MEDICAL CARE — Full financial report (2023 Y), p216", "documentId": "D-2ee6c4ff21644c7392a5420f46e71ce7", "page": 216 }, { "id": "P-811aac18fb0f44058116be85f2d967a2", "href": "https://app.finbar.com/go?id=P-811aac18fb0f44058116be85f2d967a2", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p28", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 28 }, { "id": "P-925f1c8626eb487999326f479491533b", "href": "https://app.finbar.com/go?id=P-925f1c8626eb487999326f479491533b", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p267", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 267 }, { "id": "P-eb8c1c8b4d5348d88be6c730cb3cd683", "href": "https://app.finbar.com/go?id=P-eb8c1c8b4d5348d88be6c730cb3cd683", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p31", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 31 }, { "id": "P-2e173e8ab8f940e3a66be5484f5b30d0", "href": "https://app.finbar.com/go?id=P-2e173e8ab8f940e3a66be5484f5b30d0", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p31", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 31 }, { "id": "T-7b39a412d8b5439fac390900621caddd", "href": "https://app.finbar.com/go?id=T-7b39a412d8b5439fac390900621caddd", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p350", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 350 }, { "id": "P-514ec2e5112e4f0499e0ad653820bf97", "href": "https://app.finbar.com/go?id=P-514ec2e5112e4f0499e0ad653820bf97", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p28", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 28 }, { "id": "P-02da7354e2374483b6ddd79c8d3a6c6c", "href": "https://app.finbar.com/go?id=P-02da7354e2374483b6ddd79c8d3a6c6c", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p52", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 52 }, { "id": "P-a784ab5350a14515a6fd7c015f87f5de", "href": "https://app.finbar.com/go?id=P-a784ab5350a14515a6fd7c015f87f5de", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p353", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 353 }, { "id": "T-c0163f88a0da47c2a84277c536463375", "href": "https://app.finbar.com/go?id=T-c0163f88a0da47c2a84277c536463375", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p353", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 353 }, { "id": "T-dd6ce8e784754f8ea0231b427e37f7da", "href": "https://app.finbar.com/go?id=T-dd6ce8e784754f8ea0231b427e37f7da", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p113", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 113 }, { "id": "T-7e4039cdf5294d0299af040d96522106", "href": "https://app.finbar.com/go?id=T-7e4039cdf5294d0299af040d96522106", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p370", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 370 }, { "id": "T-67d458ef27494ee8bbafb3edf4af9209", "href": "https://app.finbar.com/go?id=T-67d458ef27494ee8bbafb3edf4af9209", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p370", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 370 }, { "id": "P-3f5db0a05b684e99acc8743c0ee2752e", "href": "https://app.finbar.com/go?id=P-3f5db0a05b684e99acc8743c0ee2752e", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p32", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 32 }, { "id": "P-c4d567f19b88421a8b9149afce4140d4", "href": "https://app.finbar.com/go?id=P-c4d567f19b88421a8b9149afce4140d4", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p32", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 32 }, { "id": "P-b66d69f0452f4585904084ad50668cd4", "href": "https://app.finbar.com/go?id=P-b66d69f0452f4585904084ad50668cd4", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p160", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 160 }, { "id": "P-677e2c9fe6b94bd58a1952c747743402", "href": "https://app.finbar.com/go?id=P-677e2c9fe6b94bd58a1952c747743402", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p29", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 29 }, { "id": "P-1163a4eaa462403e9c7bad061244d9ec", "href": "https://app.finbar.com/go?id=P-1163a4eaa462403e9c7bad061244d9ec", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p29", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 29 }, { "id": "P-8d78232027664986b1821a5b7619af2d", "href": "https://app.finbar.com/go?id=P-8d78232027664986b1821a5b7619af2d", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p30", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 30 }, { "id": "P-7854d7d6997a4fa8ab48c2b9546d43a3", "href": "https://app.finbar.com/go?id=P-7854d7d6997a4fa8ab48c2b9546d43a3", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p30", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 30 }, { "id": "https://freseniusmedicalcare.com/en/about-us/history/25-years/", "href": "https://freseniusmedicalcare.com/en/about-us/history/25-years/", "label": "freseniusmedicalcare.com" }, { "id": "https://freseniusmedicalcare.com/en-us/company/our-company/news-releases/fmcna-25-anniversary-celebration/", "href": "https://freseniusmedicalcare.com/en-us/company/our-company/news-releases/fmcna-25-anniversary-celebration/", "label": "freseniusmedicalcare.com" }, { "id": "https://www.fresenius.com/node/4724", "href": "https://www.fresenius.com/node/4724", "label": "www.fresenius.com" }, { "id": "https://www.fresenius.com/node/4837", "href": "https://www.fresenius.com/node/4837", "label": "www.fresenius.com" }, { "id": "https://www.fresenius.com/node/4555", "href": "https://www.fresenius.com/node/4555", "label": "www.fresenius.com" }, { "id": "https://www.freseniusmedicalcare.com/en-us/company/our-company/news-releases/fresenius-medical-care-completes-acquisition-of-nxstage-medical/", "href": "https://www.freseniusmedicalcare.com/en-us/company/our-company/news-releases/fresenius-medical-care-completes-acquisition-of-nxstage-medical/", "label": "www.freseniusmedicalcare.com" }, { "id": "P-132714c30ae64acbba414ffedcefbb06", "href": "https://app.finbar.com/go?id=P-132714c30ae64acbba414ffedcefbb06", "label": "FRESENIUS MEDICAL CARE — Press release (2019 Y), p2", "documentId": "D-855ff832fa4c4a268f6f7c1beb15a559", "page": 2 }, { "id": "P-637047581a39412fa712a921bed2954b", "href": "https://app.finbar.com/go?id=P-637047581a39412fa712a921bed2954b", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p258", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 258 }, { "id": "P-0462157b5fa24161848308acfee8d87b", "href": "https://app.finbar.com/go?id=P-0462157b5fa24161848308acfee8d87b", "label": "FRESENIUS MEDICAL CARE — Full financial report (2024 Y), p35", "documentId": "D-3d3e0895d6fc4e73b73692652bcd6319", "page": 35 } ] }